desogestrel: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
desogestrel: clinical details
Prescribing considerations
- Exclude pregnancy and assess unexplained bleeding before initiation.
- Review breast-cancer history, thromboembolic disease, liver disease, diabetes, hypertension, mood disorders and interacting medicines.
- Counsel that bleeding may be unpredictable and persistent or unusually heavy bleeding requires assessment.
- Consider ectopic pregnancy when amenorrhoea or abdominal pain occurs.
- Assess adherence, gastrointestinal disturbance and interactions if contraceptive failure is suspected.
Contraindications and cautions
- Active venous thromboembolic disorder
- Current or previous severe hepatic disease while liver function remains abnormal
- Known or suspected sex-steroid-sensitive malignancy
- Undiagnosed vaginal bleeding
- Hypersensitivity to desogestrel or an excipient
- Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption for the selected lactose-containing product
Monitoring
- No universal laboratory-monitoring schedule is specified; follow-up should reflect individual circumstances.
- Review persistent irregular bleeding, amenorrhoea with pregnancy risk, new depression, significant blood-pressure elevation, liver symptoms or deterioration of relevant disease.
- Observe diabetes control where clinically appropriate.
- During breastfeeding, consider infant growth and development if concerns arise.
Clinical pharmacology
Desogestrel is rapidly absorbed and converted to etonogestrel, which suppresses ovulation and increases cervical-mucus viscosity. Etonogestrel is highly protein-bound and metabolised through hydroxylation, dehydrogenation and conjugation pathways.
Formulation and product differences
- The selected Zelleta/Desogestrel product is a round, white to off-white, uncoated tablet supplied in calendar blister packs.
- The selected product contains lactose. Excipients and tablet appearance may differ between brands; check the specific product information.
desogestrel preparations and strengths
Tablet
Route: Oral
Strengths: 75 micrograms
desogestrel interactions
Check prescribed, non-prescription and herbal medicines because interactions can alter contraceptive protection or other medicine levels.
Enzyme-inducing antiseizure medicines, including carbamazepine, phenytoin, primidone, phenobarbital, oxcarbazepine and topiramate
Can lower etonogestrel exposure, causing breakthrough bleeding or contraceptive failure; additional or alternative contraception may be required.
Rifampicin or rifabutin
Can accelerate hormone clearance and reduce contraceptive protection.
St John’s wort
Can reduce desogestrel’s effectiveness; discuss its use with a pharmacist or prescriber.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.